RT Journal
A1 Leach MJ
T1 COmplementary health practices
JF JAMA
JO JAMA
YR 2012
FD August 1
VO 308
IS 5
SP 452
OP 453
DO 10.1001/jama.2012.8159
UL http://dx.doi.org/10.1001/jama.2012.8159
AB 
To the Editor: Dr Offit1 presented a number of interesting points in his discussion of the value of research conducted by NCCAM. However, several warrant further discussion. First, advising NCCAM to refrain from funding studies of therapies that lack biological plausibility would be unreasonable. Such action would unnecessarily deny populations timely access to much-needed clinical evidence required to make informed health care decisions. For particularly vulnerable patient populations who might be exposed to unscrupulous health care services or practitioners, such action could have substantial implications for the health and well-being of the patient.